Deutsche Bank Maintains Buy Rating on Medicis

Deutsche Bank is maintaining its Buy rating on Medicis Pharmaceutical MRX. “The outlook for Medicis' flagship Solodyn franchise has improved significantly – based on a strong switch thus far to the ‘new' protected doses and the key Q1 settlement with Teva,” Deutsche Bank writes. “Hence, we continue to see MRX capable of generating longterm EPS growth of 12%+, driven by its acne and aesthetics brands, as well as its emerging development pipeline.” Medicis Pharmaceutical closed Monday at $36.65.